A Clinical Case of Nosocomial Pneumonia as a Complication of COVID-19: How to Balance Benefits and Risks of Immunosuppressive Therapy?

We report a Russian case of a 61-year-old male patient with confirmed COVID-19 infection who developed nosocomial pneumonia complicated by lung abscess associated with multi-drug-resistant isolates of and , which could have been provoked due to the immunosuppressive therapy. We discuss the existing literature highlighting the issue of the prudent balance between benefits and risks when prescribing immunomodulators to hospitalized patients with COVID-19 due to the risk of difficult-to-treat nosocomial infections caused by MDR Gram-negative bacterial pathogens. Currently, there is evidence of a substantial positive effect of dexamethasone on the course of COVID-19 in patients requiring supplemental oxygen or anti-interleukin-6 drugs in individuals with prominent systemic inflammation.

Antimicrobial Dispensing Practice in Community Pharmacies in Russia during the COVID-19 Pandemic.

COVID-19 has had a significant impact on health care systems, including drug use. The present study aimed to evaluate the patterns of community supply of antimicrobials from community pharmacies during the COVID-19 pandemic in five cities of Russia. In a cross-sectional study, a random sample of pharmacies reported all episodes of antimicrobials supply during a one-week period.

[Fosfomycin: potential and perspectives for use in urological practice].

The increase in infections caused by multidrug-resistant microorganisms is currently one of the most serious medical issues. In fact, antimicrobial resistance is viewed by the World Health Organization as one of the most serious threats to health worldwide. The problem is exacerbated by the lack of new antibiotics with respective benefits for the treatment of multidrug-resistant bacteria.